RCG
ASND icon

Rock Creek Group’s Ascendis Pharma A/S ASND Stock Holding History

Rock Creek Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,006
Closed -$487K – 179
2021
Q4 		$487K Buy
+4,006
New +$596K 0.07% 87

Other funds holding ASND

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rock Creek Group's ASND Position: Q1 2022 in Review

Rock Creek Group sold out of Ascendis Pharma A/S (ASND) in Q1 2022, closing a stake of 4,006 shares — an estimated $487K sold.

Rock Creek Group first reported a position in ASND in Q4 2021 and held it in 1 quarter. The position peaked at $487K in Q4 2021. 178 funds tracked by Wall St. Rank hold ASND as of Q1 2022.

  • Rock Creek Group reported no remaining Ascendis Pharma A/S position as of Q1 2022 after selling out during the quarter.
  • Rock Creek Group sold 4,006 Ascendis Pharma A/S shares in Q1 2022, an estimated $487K.
  • Rock Creek Group first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 1 quarter.
  • Rock Creek Group's Ascendis Pharma A/S position peaked at $487K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2022.

Based on Rock Creek Group's 13F filing for Q1 2022, filed 11 May 2022.